CIAM
AMLX icon

Caitong International Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Caitong International Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$503 Sell
28
-8
-22% -$124 ﹤0.01% 1730
2026
Q1 		$500 Sell
36
-3,823
-99% -$53.8K ﹤0.01% 1649
2025
Q4 		$46.6K Buy
3,859
+3,493
+954% +$47.4K 0.01% 733
2025
Q3 		$4.97K Sell
366
-2,547
-87% -$24K ﹤0.01% 1227
2025
Q2 		$18.7K Buy
2,913
+684
+31% +$3.33K 0.01% 517
2025
Q1 		$7.89K Buy
+2,229
New +$7.93K 0.01% 916

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Caitong International Asset Management's AMLX Position: Q2 2026 in Review

Caitong International Asset Management reduced its Amylyx Pharmaceuticals (AMLX) stake by 22% in Q2 2026, selling an estimated $124 and leaving 28 shares worth $503. The position accounts for ﹤0.01% of the portfolio, ranked #1730.

Caitong International Asset Management first reported a position in AMLX in Q1 2025 and has held it in 6 quarters since. The position peaked at $46.6K in Q4 2025. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Caitong International Asset Management held 28 shares of Amylyx Pharmaceuticals worth $503 as of Q2 2026.
  • Caitong International Asset Management sold 8 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $124.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1730 holding.
  • Caitong International Asset Management first reported a position in Amylyx Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Caitong International Asset Management's Amylyx Pharmaceuticals position peaked at $46.6K in Q4 2025.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.